Are MAO-A deficiency states in the general population and in putative high-risk populations highly uncommon?
Lack of monoamine oxidase A (MAO-A) due to either Xp chromosomal deletions or alterations in the coding sequence of the gene for this enzyme are associated with marked changes in monoamine metabolism and appear to be associated with variable cognitive deficits and behavioral changes in humans and in transgenic mice. In mice, some of the most marked behavioral changes are ameliorated by pharmacologically-induced reductions in serotonin synthesis during early development, raising the question of possible therapeutic interventions in humans with MAO deficiency states. At the present time, only one multi-generational family and a few other individuals with marked MAO-A deficiency states have been identified and studied in detail. Although MAO deficiency states associated with Xp chromosomal deletions were identified by distinct symptoms (including blindness in infancy) produced by the contiguous Norrie disease gene, the primarily behavioral phenotype of individuals with the MAO mutation is less obvious. This paper reports a sequential research design and preliminary results from screening several hundred volunteers in the general population and from putative high-risk groups for possible MAO deficiency states. These preliminary results suggest that marked MAO deficiency states are very rare.
KeywordsAttention Deficit Hyperactivity Disorder Monoamine Oxidase Attention Deficit Hyperactivity Disorder Adult Monoamine Metabolite MAOA Gene
Unable to display preview. Download preview PDF.
- Berlin FS, Hunt WP, Malin HM, Dyer A, Lahne GK, Dean S (1991) A five-year plus follow-up survey of criminal recidivism within a treated cohort of 406 pedophiles, 111 exhibitionists and 109 sexual aggressives: issues and outcome. Am J Forensic Psychiatry 12(3): 5–28Google Scholar
- Brunner HG, Nelen MR, van Zandvoort P, Abeling NG, van Gennip AH, Wolters EC, Kuiper MA, Ropers HH, van Oost BA (1993b) X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. Am J Hum Genet 52: 1032–1039PubMedGoogle Scholar
- Collins FA, Murphy DL, Reiss AL, Sims KB, Lewis JG, Freund L, Karoum F, Zhu D, Maumenee IH, Antonarakis SE (1992) Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp 11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. Am J Med Genet 42: 127–134PubMedCrossRefGoogle Scholar
- Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ (1986) Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 32: 2030–2033PubMedGoogle Scholar
- Higley JD, Thompson WW, Champoux M, Goldman D, Hasert MF, Kraemer GW, Scanlan JM, Suomi SJ, Linnoila M (1993) Paternal and maternal genetic and environmental contributions to cerebrospinal fluid monoamine metabolites in rhesus monkeys (macaca mulatta). Arch Gen Psychiatry 50: 615–623PubMedCrossRefGoogle Scholar
- Kopin IJ, Blombery P, Ebert MH, Gordon EK, Jimerson DC, Markey SP, Polinsky RJ (1984) Disposition and metabolism of MHPG-CD3 in humans: plasma MHPG as the principal pathway of norepinephrine metabolism and as an important determinant of CSF levels of MHPG. Adv Biochem Psychopharmacol 39: 57–68PubMedGoogle Scholar
- Lenders JWM, Eisenhofer G, Abeling NGGM, Berger W, Murphy DL, Konings CH, Wagemakers LMB, Kopin IJ, Karoum F, van Gennip AH, Brunner HG (1996) Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J Clin Invest 97: 1–10CrossRefGoogle Scholar
- Murphy DL, Pickar D, Jimerson D, Cohen RM, Garrick NA, Karoum F, Wyatt RJ (1981) Biochemical indices of the effects of the selective MAO inhibitors clorgyline, pargyline and deprenyl in man. In: Usdin E, Dahl SG, Gram LF, Ligjaerde O (eds) Clinical pharmacology in psychiatry: neuroleptic and antidepressant research. Macmillan, London, pp 307–316Google Scholar